Novavax used aborted fetal cells in testing phase
The Food and Drug Administration (FDA) yesterday issued an emergency use authorization for Novavax’s protein-based COVID-19 vaccine, which means that once the Centers for Disease Control and Prevention (CDC) formally signs off on the FDA’s authorization, the Novavax shot can be given to adults aged 18 and older.
Despite Novavax’s public statements that its COVID-19 vaccine does not have any connection to abortion-derived cell lines, evidence from a private letter and Novavax’s own published study shows that the HEK293 aborted fetal cell line was used in the testing phase.
Novavax COVID Shot Associated With Aborted Fetal Cells
Liberty Counsel Press Release - June 9, 2022
Despite erroneous claims that Novavax’s COVID-19 injection (NVX-CoV2373) does not have any connection to abortion-derived cell lines, evidence from Novavax’s own published study shows otherwise.
While Novavax claims that no human fetal-derived cell lines or tissue, including HEK293 cells, were used in the development, manufacture, or production of the Novavax COVID-19 shots, it is not true that there is no association with abortion because an aborted fetal cell line was used in the testing phase of Novavax.
Novavax’s published study, “Structural Analysis of Full-Length SARS-CoV-2 Spike Protein From an Advanced Vaccine Candidate,” shows that the HEK293 aborted fetal cell line was used in the testing phase. The HEK293 cell line was originally harvested from the kidney of an aborted baby girl in 1973.
In a letter obtained by the Charlotte Lozier Institute, Novavax admits that HEK293 cells were indeed used as part of the testing phase for NVX-CoV2373:
Testing was conducted to compare the structural integrity of the SARS-CoV-2 spike protein produced in the Sf9 insect cells versus the spike protein produced in the mammalian human embryonic kidney HEK 293F cells. The comparison determined the Sf9 cell technology produced spike proteins were comparable in structural integrity as the spike proteins produced in the HEK 293F cell.
Novavax’s COVID-19 shot has now been recommended for emergency use authorization (EUA) in the U.S. for adults 18 and older by the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee. This came after they voted 21 to 0 with one abstention when asked if the benefits of the two-dose “vaccine” series outweigh the risks for U.S. adults “based on the totality of scientific evidence available,” according to the live-streamed committee meeting.
The Novavax shot, like mRNA COVID injections, has also demonstrated increased risk for heart inflammation. Several cases of myocarditis and pericarditis were observed in the trial participants within two weeks of injection.
Similar to Moderna and BioNTech, Novavax has never successfully brought a product to market in its 33-year history. The company has zero track record of success, safety, and/or efficacious products.
Novavax and the FDA panel have already stated that two doses of the Novavax shot will not be enough to “protect” people from the virus and repeated boosting will be necessary. The shot was developed over two years ago, but there is no trial data on the Omicron variant.
The FDA said: “Relevant data to assess effectiveness of NVX-CoV2373 (Novavax shot) against the Omicron variant and sublineages, including observational data from use in other countries where the vaccine has been deployed, are currently unavailable.”
Novavax used aborted fetal cell lines in the testing phase, and it is already known that Novavax increases the risk of myocarditis. But the FDA continues to rubber stamp pharmaceutical companies with no history of success so long as the product is associated with COVID-19. The FDA is supposed to be the watchdog to protect public health, but, sadly, the FDA has become the lapdog of Big Pharma.
-Mat Staver, Liberty Counsel founder and chairman